{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_protein_modifications_structuralModifications_molecularFragment_refPname in Protein Structural Modification Substance Name (approximate match)
Status:
Investigational
Source:
INN:efinopegdutide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efocipegtrutide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegapamodutide [INN]
Source URL:
Class:
PROTEIN
Status:
Designated
Source:
FDA ORPHAN DRUG:810621
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Elcatonin is a physio-chemically stable calcitonin derivative in which the disulfide bond between cysteine residues at positions 1 and 7 of eel calcitonin has been replaced by an ethylene bond. The primary pharmacological effect of Elcatonin is its activity at specific osteoclast receptors, resulting in diminished osteoclast activity at extremely low concentrations. Elcatonin inhibits the bones autolysis and renal calcium, phosphorus, and sodium reabsorption thus keeps blood calcium at a normal level. In clinical settings, once-weekly intramuscular injection of elcatonin has been shown to significantly increase bone mineral density within 6 months and to alleviate post-fracture pain and improve Quality of life in osteoporosis
Status:
US Approved Rx
(2021)
Source:
NDA214231
(2021)
Source URL:
First approved in 2021
Source:
NDA214231
Source URL:
Class:
PROTEIN